Walter Ryan, DO
Allergy & Immunology · Nashua, NHNPI 1073503843
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,321 of the $7,601 with a category attached, or 70.0%. 26 manufacturers reported payments, led by Pharming Healthcare, Inc. at 31.5% of the total. Reporting peaked in 2021 at $3,438 and has fallen 96.0% since, to $137 in 2025.
Across 242 payments — averaging $31.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharming Healthcare, Inc.$2K
- GSK$1K
- AstraZeneca$951
- Takeda Pharmaceuticals U.S.A., Inc.$409
- Regeneron Healthcare Solutions, Inc.$307
- Optinose US, Inc.$274
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$2,25030%
- Food & beverage$5,32170%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharming Healthcare, Inc. | 8 | $2,397 |
| GSK | 74 | $1,481 |
| AstraZeneca | 47 | $951 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $409 |
| Regeneron Healthcare Solutions, Inc. | 5 | $307 |
| Optinose US, Inc. | 13 | $274 |
| Boehringer Ingelheim | 12 | $253 |
| Pfizer | 11 | $252 |
| Sanofi | 7 | $187 |
| Incyte Corporation | 3 | $175 |
| CSL Behring | 6 | $122 |
| Genentech USA, Inc. | 5 | $116 |
| Alk-abello, Inc | 5 | $111 |
| Amgen(2 entities) | 5 | $109 |
| Novartis | 4 | $89 |
| Teva Pharmaceuticals USA, Inc. | 5 | $75 |
| Biocryst US Sales Co., LLC | 2 | $56 |
| Kaleo, Inc. | 2 | $46 |
| Shire North American Group Inc | 2 | $42 |
| Octapharma USA, Inc. | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Merck | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| USWM, LLC | 1 | $16 |
| Blueprint Medicines Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in New Hampshireto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $19,818 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $19,261 |
| Atrovent HfaIpratropium Bromide | 12 | $6,279 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $6,268 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,989 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,237 |
| Epinephrine | 24 | $2,522 |
| Azelastine Hcl | 80 | $2,300 |
| Wixela InhubFluticasone Propion/Salmeterol | 37 | $2,118 |
| Levocetirizine Dihydrochloride | 96 | $1,487 |
| Desloratadine | 17 | $1,417 |
| Olopatadine Hcl | 12 | $1,092 |
| Fluticasone Propionate | 65 | $1,068 |
| Ipratropium Bromide | 59 | $1,011 |
| Mometasone Furoate | 14 | $751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $1,481 | $32,07560 claims |
| AstraZenecaBreztri Aerosphere | $951 | $19,26125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in New Hampshireon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Nashua
- Amitha HarishNashua$526
- Anne MiranowskiLebanon$9K
- Karen Hsu BlatmanLebanon$9K
- Ashok ShahNewmarket$5K
- Ogechukwu NdumLebanon$1K
- Mark WindtNorth Hampton$970
- Donald WoodmanseeLebanon$122
- Susan MozzicatoLebanon$28
- Sarah Taylor BlackKeene$25
- An HuynhLebanon$19
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.